Latest From Novavax Inc.
Currently focused on HBV, Altimmune gets preclinical NASH candidate that offers dual agonism of GLP-1 and glucagon receptors. Nimbus expands alliance with Celgene into IO, Merck & Co. partners with Skyhawk.
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
Enanta's N-protein inhibitor EDP-938 hit a pair of endpoints in a Phase IIa challenge study, but real-world testing may be a higher hurdle. The company believes its therapeutic approach is more effective than fusion protein prophylactic approaches.
Novavax’s shares plunged 67% on news that its Phase III trial for RSV had failed, but are there signs of life for the product?
- Drug Delivery
- Specialty Pharmaceuticals
- Therapeutic Areas
- Infectious & Viral Diseases
- North America
- Parent & Subsidiaries
- Novavax Inc.
- Senior Management
Stanley C Erck, Pres. & CEO
John J Trizzino, SVP, CBO & CFO
Gregory M Glenn, MD, Pres., R&D
Russell P Wilson, SVP, Bus. Dev.
Louis F Fries, MD, CMO
- Contact Info
Phone: (240) 268-2000
20 Firstfield Rd.
Gaithersburg, MD 20878
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.